Lifebrite Hospital Group of Early LLC

Lifebrite Hospital Group of Early LLC was paid $61K by Medicaid between Jan 2018 and Mar 2019, across 31 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 24% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,355	$46K
2019	103	$15K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	24%	103	83	$15K
80363		7.8%	137	121	$5K
80347		5.3%	137	121	$3K
80351		4.8%	137	121	$3K
80321		3.5%	78	72	$2K
80370		3.3%	137	121	$2K
80357		3.3%	136	120	$2K
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.2%	20	20	$2K
80356		3.1%	137	121	$2K
80359		3.1%	137	121	$2K
80366		3.0%	137	121	$2K
80368		3.0%	137	121	$2K

19 more codes

80373		2.9%	137	$2K
80355		2.8%	137	$2K
80367		2.7%	137	$2K
80336		2.6%	80	$2K
80332		2.5%	137	$2K
80372		2.3%	137	$1K
80348		2.3%	137	$1K
80358		2.2%	137	$1K
80349		2.1%	136	$1K
80324		2.1%	137	$1K
80353		2.0%	137	$1K
80345		2.0%	137	$1K
80337		1.7%	53	$1K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	64	$500.00
83986		<1%	137	$459.00
81003		<1%	137	$306.00
86684		<1%	17	$79.72
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	16	$45.24
87070		<1%	15	$32.49

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDUNN, MORGAN (CEO)